CH | EN

News

News Center

Company News

Industry News

Science Popularization

Video

More great news! Jiuzhitang Maker has secured funding from Beijing's major science and technology project.

2020-01-23

Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. recently received significant funding from Beijing's major science and technology project. The company's proposed project, "Preclinical Study of Human Bone Marrow Mesenchymal Stem Cells for the Treatment of Acute Stroke," has been officially approved (Project No. Z191100001519004).

This research project focuses on conducting preclinical registration studies for human bone marrow mesenchymal stem cells, strictly adhering to pharmaceutical research standards. The study plan encompasses pharmacological, toxicological, and pharmacodynamic mechanism investigations. Additionally, the toxicology study protocol is designed in accordance with the ICH M3 and ICH S6 guidelines established by the International Council for Harmonisation (ICH), aiming to support the clinical application of this therapy in treating acute ischemic stroke in both male and female patients.

This project has earned recognition from Beijing Municipal Science & Technology Commission and industry experts, highlighting the company's potential to lead industry advancements in stem-cell-based pharmaceuticals—and serving as a testament to its robust technological capabilities.

The successful implementation of the project will lay the groundwork for future clinical studies on bone marrow mesenchymal stem cell therapy for acute stroke, while also enriching Jiuzhitang Maker’s R&D pipeline.

Jiuzhitang Maker has filled a domestic gap by introducing Stemedica's globally leading, clinical-grade stem cell preparation platform, enabling the company to master the core technologies for scalable, standardized, and traceable stem cell production.

The company has established a production platform at Beijing Daxing Biomedical Base—known as "China's Pharmaceutical Valley"—that complies with both Chinese and U.S. cGMP-standard quality systems. Additionally, Meike was recognized by the Daxing District Development and Reform Commission and the Biomedical Base Committee as one of the district’s ten key enterprises. The company’s large-scale stem cell production platform project, selected as one of Daxing District’s 10 flagship initiatives, has been recommended for inclusion as a priority project under Beijing’s high-end, sophisticated, and cutting-edge industries. Meanwhile, Jiuzhitang Maker has been consecutively certified as both a "Zhongguancun High-Tech Enterprise" and a "National High-Tech Enterprise."

Jiuzhitang Maker extends New Year greetings: 2020—let’s honor the journey we’ve taken so far and set forth anew with gratitude.

Great news! Jiuzhitang Maker has been honored with the title of "Zhongguancun Golden Seed Enterprise."

Here is the title—h1 placeholder text

Online Message

COOKIES

Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy

COOKIES

required

These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.

analyze

These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.

Feature

These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.

advertise

These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.

Business license